Aladar Szalay Sells 14,331 Shares of Genelux Co. (NASDAQ:GNLX) Stock

Genelux Co. (NASDAQ:GNLX) major shareholder Aladar Szalay sold 14,331 shares of Genelux stock in a transaction that occurred on Monday, April 22nd. The stock was sold at an average price of $3.53, for a total transaction of $50,588.43. Following the sale, the insider now owns 1,285,794 shares in the company, valued at $4,538,852.82. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Large shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.

Aladar Szalay also recently made the following trade(s):

• On Wednesday, April 24th, Aladar Szalay sold 8,064 shares of Genelux stock. The stock was sold at an average price of $3.50, for a total transaction of $28,224.00.
• On Tuesday, April 16th, Aladar Szalay sold 48,683 shares of Genelux stock. The shares were sold at an average price of $3.53, for a total value of $171,850.99.

Genelux Price Performance

GNLX stock opened at $3.32 on Friday. The stock has a 50-day moving average price of $5.76 and a 200-day moving average price of $10.90. Genelux Co. has a 1-year low of $3.07 and a 1-year high of $40.98.

Genelux (NASDAQ:GNLX) last issued its earnings results on Friday, March 29th. The company reported ($0.25) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.04). As a group, equities research analysts forecast that Genelux Co. will post -0.81 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Vanguard Group Inc. raised its holdings in shares of Genelux by 1,660.1% during the third quarter. Vanguard Group Inc. now owns 980,993 shares of the company’s stock valued at $24,025,000 after purchasing an additional 925,258 shares during the period. D.A. Davidson & CO. bought a new position in Genelux in the third quarter worth approximately $237,000. Advisor Resource Council acquired a new stake in Genelux in the fourth quarter valued at approximately $233,000. Barclays PLC increased its holdings in shares of Genelux by 516.4% during the third quarter. Barclays PLC now owns 3,384 shares of the company’s stock valued at $83,000 after acquiring an additional 2,835 shares in the last quarter. Finally, Whittier Trust Co. acquired a new position in shares of Genelux during the third quarter worth approximately $175,000. Institutional investors and hedge funds own 37.33% of the company’s stock.

Wall Street Analyst Weigh In

GNLX has been the topic of a number of analyst reports. HC Wainwright reduced their price target on Genelux from $35.00 to $32.00 and set a “buy” rating on the stock in a research report on Tuesday, April 2nd. Benchmark reissued a “speculative buy” rating and set a $30.00 target price on shares of Genelux in a research report on Wednesday, April 3rd.

Genelux Company Profile

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.